$333 Million is the total value of TCG Crossover Management, LLC's 21 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 31.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ISEE | Buy | IVERIC BIO INC | $69,570,000 | +148.2% | 3,877,903 | +33.1% | 20.87% | +75.2% |
| COGT | COGENT BIOSCIENCES INC | $51,937,000 | +65.4% | 3,481,042 | 0.0% | 15.58% | +16.8% | |
| GERN | Sell | GERON CORP | $28,351,000 | +21.2% | 12,115,926 | -19.7% | 8.50% | -14.4% |
| VRDN | Sell | Viridian Therapeutics Inc | $23,874,000 | +57.0% | 1,164,000 | -11.4% | 7.16% | +10.9% |
| SLN | New | SILENCE THERAPEUTICS PLCadrs | $21,122,000 | – | 2,104,875 | +100.0% | 6.34% | – |
| CBAY | CYMABAY THERAPEUTICS INC | $20,669,000 | +18.6% | 5,905,400 | 0.0% | 6.20% | -16.2% | |
| KURA | Buy | KURA ONCOLOGY INC | $18,422,000 | -13.9% | 1,348,642 | +15.5% | 5.52% | -39.2% |
| ACRS | ACLARIS THERAPEUTICS INC | $18,021,000 | +12.8% | 1,144,939 | 0.0% | 5.40% | -20.4% | |
| AVTE | Buy | AEROVATE THERAPEUTICS INC | $15,910,000 | +14.4% | 959,572 | +7.9% | 4.77% | -19.2% |
| Sell | ENTRADA THERAPEUTICS INC | $10,121,000 | +25.2% | 642,189 | -3.2% | 3.04% | -11.6% | |
| ALLK | New | ALLAKOS INC | $10,058,000 | – | 1,643,500 | +100.0% | 3.02% | – |
| AKUS | AKOUOS INC | $9,126,000 | +44.1% | 1,350,006 | 0.0% | 2.74% | +1.7% | |
| Buy | TYRA BIOSCIENCES INC | $8,313,000 | +29.7% | 945,707 | +5.5% | 2.49% | -8.4% | |
| MOONLAKE IMMUNOTHERAPEUTICS | $7,760,000 | +47.8% | 1,000,000 | 0.0% | 2.33% | +4.4% | ||
| MRUS | MERUS BV | $6,009,000 | -11.5% | 300,000 | 0.0% | 1.80% | -37.5% | |
| TANGO THERAPEUTICS INC | $4,244,000 | -20.1% | 1,172,250 | 0.0% | 1.27% | -43.6% | ||
| MGTA | MAGENTA THERAPEUTICS INC | $2,995,000 | +17.5% | 2,124,122 | 0.0% | 0.90% | -17.1% | |
| ZLAB | Sell | ZAI LAB LTD-ADRadrs | $2,489,000 | -24.5% | 72,777 | -23.4% | 0.75% | -46.6% |
| MDGL | New | MADRIGAL PHARMACEUTICALS INC | $1,950,000 | – | 30,000 | +100.0% | 0.58% | – |
| ALPN | Sell | ALPINE IMMUNE SCIENCES INC | $1,833,000 | -62.8% | 254,569 | -56.0% | 0.55% | -73.7% |
| ELEV | ELEVATION ONCOLOGY INC | $627,000 | -19.3% | 555,000 | 0.0% | 0.19% | -43.0% | |
| Exit | Pardes Biosciences, Inc. | $0 | – | -59,039 | -100.0% | -0.08% | – | |
| ANAB | Exit | AnaptysBio, Inc. | $0 | – | -58,515 | -100.0% | -0.50% | – |
| ETNB | Exit | 89bio, Inc. | $0 | – | -1,133,196 | -100.0% | -1.55% | – |
| KDNY | Exit | Chinook Therapeutics, Inc. | $0 | – | -796,460 | -100.0% | -5.92% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| COGENT BIOSCIENCES INC | 8 | Q3 2023 | 15.6% |
| AEROVATE THERAPEUTICS INC | 8 | Q3 2023 | 6.5% |
| TYRA BIOSCIENCES INC | 8 | Q3 2023 | 6.2% |
| ENTRADA THERAPEUTICS INC | 8 | Q3 2023 | 5.3% |
| MERUS N.V. | 8 | Q3 2023 | 3.4% |
| IVERIC BIO INC | 7 | Q2 2023 | 24.4% |
| Geron Corporation | 7 | Q3 2023 | 12.4% |
| ACLARIS THERAPEUTICS INC | 7 | Q2 2023 | 7.9% |
| KURA ONCOLOGY INC | 7 | Q3 2023 | 9.1% |
| ALPINE IMMUNE SCIENCES INC | 7 | Q2 2023 | 7.6% |
View TCG Crossover Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Silence Therapeutics plc | August 19, 2022 | 6,314,625 | 5.9% |
| CymaBay Therapeutics, Inc. | November 29, 2021 | 5,905,400 | 7.0% |
| Cogent Biosciences, Inc. | November 17, 2021 | 2,716,042 | 6.8% |
| Tyra Biosciences, Inc. | September 29, 2021 | 937,500 | 2.2% |
| Viridian Therapeutics, Inc.\DE | September 29, 2021 | 1,314,000 | 8.2% |
View TCG Crossover Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| SC 13G | 2022-08-19 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-18 |
View TCG Crossover Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.